GSK1325756
Showing 1 - 15 of 15
Pulmonary Disease, Chronic Obstructive Trial in Overland Park (Danirixin, Omeprazole)
Completed
- Pulmonary Disease, Chronic Obstructive
-
Overland Park, KansasGSK Investigational Site
Apr 27, 2021
Pulmonary Disease, Chronic Obstructive Trial in Dundee (Danirixin, Placebo, Rescue medication)
Terminated
- Pulmonary Disease, Chronic Obstructive
- Danirixin
- +3 more
-
Dundee, United KingdomGSK Investigational Site
Feb 26, 2021
Virus Diseases Trial in Worldwide (Danirixin 15 mg FBE, Danirixin 50 mg FBE, Placebo)
Terminated
- Virus Diseases
- Danirixin 15 mg FBE
- +3 more
-
Stamford, Connecticut
- +7 more
Nov 20, 2020
Pulmonary Disease, Chronic Obstructive Trial in United States (Danirixin 35 mg tablets, Placebo, Metered dose inhaler (MDI)
Terminated
- Pulmonary Disease, Chronic Obstructive
- Danirixin 35 mg tablets
- +3 more
-
Birmingham, Alabama
- +10 more
Jul 14, 2020
Virus Diseases Trial in Australia, South Africa, United States (GSK1325756 (Danirixin), Placebo To Match GSK1325756, Oseltamivir
Completed
- Virus Diseases
- GSK1325756 (Danirixin)
- +3 more
-
Palmetto Bay, Florida
- +32 more
Jul 10, 2019
Pulmonary Disease, Chronic Obstructive Trial in Tokyo (GSK1325756H, Placebo)
Completed
- Pulmonary Disease, Chronic Obstructive
- GSK1325756H
- Placebo
-
Tokyo, Japan
- +1 more
Jan 14, 2019
Pulmonary Disease, Chronic Obstructive Trial in Overland Park (Danirixin HBr 50 mg IR Tablet, Danirixin FB 50 mg IR Tablet,
Completed
- Pulmonary Disease, Chronic Obstructive
- Danirixin HBr 50 mg IR Tablet
- +2 more
-
Overland Park, KansasGSK Investigational Site
Jul 20, 2018
Pulmonary Disease, Chronic Obstructive Trial in London (GSK1325756, Placebo tablet)
Completed
- Pulmonary Disease, Chronic Obstructive
- GSK1325756
- Placebo tablet
-
London, United KingdomGSK Investigational Site
Jul 5, 2017
Nutritional Status Trial in Minneapolis (GSK1325756)
Completed
- Nutritional Status
- GSK1325756
-
Minneapolis, MinnesotaGSK Investigational Site
Jun 13, 2017
Pulmonary Disease, Chronic Obstructive Trial in London (GSK1325756, Placebo)
Completed
- Pulmonary Disease, Chronic Obstructive
- GSK1325756
- Placebo
-
London, United KingdomGSK Investigational Site
Jun 13, 2017
Pulmonary Disease, Chronic Obstructive Trial in Nottingham (GSK1325756)
Completed
- Pulmonary Disease, Chronic Obstructive
- GSK1325756
-
Nottingham, United KingdomGSK Investigational Site
Jun 9, 2017
Pulmonary Disease, Chronic Obstructive Trial in Worldwide (Danirixin, Danirixin matching , Standard of care)
Completed
- Pulmonary Disease, Chronic Obstructive
- Danirixin
- +3 more
-
Birmingham, Alabama
- +63 more
Oct 6, 2020
Infections, Respiratory Tract Trial in Overland Park (GSK1325756 Solution, GSK1325756 Solution Matching Placebo, GSK1325756
Completed
- Infections, Respiratory Tract
- GSK1325756 Solution
- +3 more
-
Overland Park, KansasGSK Investigational Site
May 12, 2017
Infections, Respiratory Syncytial Virus Trial in Syracuse (Danirixin, CXCL1)
Completed
- Infections, Respiratory Syncytial Virus
- Danirixin
- CXCL1
-
Syracuse, New YorkGSK Investigational Site
May 5, 2017
Pulmonary Disease, Chronic Obstructive Trial in Germany, United States (Danirixin, Placebo)
Completed
- Pulmonary Disease, Chronic Obstructive
- Danirixin
- Placebo
-
Birmingham, Alabama
- +15 more
Jun 13, 2017